Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25311437 | 1.00 | CDK4 (0.56) | CDK4CCND1ALDH1A1HSD11B1SMN1; SMN2 | |
| SCHEMBL30515255 | 0.83 | POLB (0.66) | ALDH1A1POLBKDM4EKMT2ALMNA | |
| SCHEMBL11767169 | 0.83 | POLB (0.66) | ALDH1A1POLBKDM4EKMT2ALMNA | |
| SCHEMBL1557657 | 0.80 | ALDH1A1 (0.69) | CDK4CCND1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1559575 | 0.80 | CDK4 (0.63) | CDK4CCND1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL11774525 | 0.78 | MAPK14 (0.44) | KDM4EMAPK14 | |
| SCHEMBL14357727 | 0.78 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL25310211 | 0.75 | CDK4 (0.54) | CDK4CCND1ALDH1A1HSD11B1SMN1; SMN2 | |
| SCHEMBL30515257 | 0.75 | CDK4 (0.54) | CDK4CCND1ALDH1A1HSD11B1SMN1; SMN2 | |
| SCHEMBL13936100 | 0.75 | MAPK14 (0.76) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | CDK4 1688/4885CCND1 2260/4885ALDH1A1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.